aibioMereo BioPharma faces securities class action naming its CEO and chief scientific officer
Tickers MREO
Dodge v. Mereo Biopharma Group PLC (1:26-cv-988) was filed Feb. 4, 2026 in the Southern District of New York. The lead plaintiff filed an amended complaint on July 13, 2026.
Key facts
- Company
- Mereo BioPharma Group plc (NASDAQ: MREO)
- News type
- Legal
- Primary source
- Mereo BioPharma 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)
Mereo BioPharma Group plc (Nasdaq: MREO) is a defendant in a putative securities class action in the U.S. District Court for the Southern District of New York, according to its 10-Q filed Aug 11, 2026. The suit names the company, chief executive officer Denise Scots-Knight and chief scientific officer John Lewicki. The lead plaintiff filed an amended complaint on July 13, 2026, and no response has been filed.
The complaint was filed on Feb. 4, 2026 and is captioned Dodge v. Mereo Biopharma Group PLC, No. 1:26-cv-988. The company, Scots-Knight and Lewicki are the defendants. The 10-Q names no other officers and no directors as defendants.
The case
The complaint alleges that the defendants violated federal securities law by making false and misleading statements regarding the company's business and operations. The 10-Q does not give a class period, identify the statements at issue or say which sections of the securities laws the plaintiff invokes. The plaintiff seeks damages allegedly sustained by her and the putative class, plus interest and legal and other costs and fees.
Mereo described the suit in its 10-K for 2025, filed March 19, 2026, in nearly the same words. There it said that, because of the nature of the matter and inherent uncertainties, it was not possible to evaluate the likelihood of an unfavorable outcome or estimate the amount or range of potential loss, if any.
Defendants
The defendants named in the filings are Mereo BioPharma Group plc, Denise Scots-Knight, its chief executive officer, and John Lewicki, its chief scientific officer. The 10-Q refers to the company and the two executives together as "the Defendants".
Where it stands
On April 29, 2026, the court appointed a lead plaintiff and lead counsel. The lead plaintiff filed the amended complaint on July 13, 2026. The 10-Q says no responsive pleadings have been filed to date.
Mereo says it intends to vigorously defend the action. At this early stage, it says, it can neither predict the ultimate outcome nor estimate any range of possible losses. Apart from this suit, the company said it was not a party to any material litigation and had no material contingency reserves for any liabilities as of June 30, 2026 and Dec. 31, 2025.
Why it matters to shareholders
The filings give no figure for defense costs and do not mention insurance or indemnification for the two executives. They also do not say what the complaint's alleged misstatements concern, and they do not describe the lead plaintiff's amended complaint beyond its filing date.
Other disclosures from the same period give context, though no filing links them to the suit. Mereo's two late-stage candidates are setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. In December 2025 the company and its partner Ultragenyx announced that the Phase 3 Orbit and Cosmic studies of setrusumab did not achieve their primary endpoint.
Mereo's American Depositary Shares trade on the Nasdaq Capital Market. On Feb. 17, 2026, the company received a Nasdaq notice that it no longer met the $1.00 minimum bid price requirement. On Aug. 18, 2026 it received a second notice giving it until Feb. 16, 2027 to regain compliance, according to an 8-K filed Aug 19. On Aug. 11, 2026 it signed an option and license agreement with Sentynl Therapeutics for alvelestat under which, on option exercise, it is eligible for $40 million in upfront and R&D payments, as disclosed in an 8-K of the same date.